ResMed (RMD) is having a Dividend Yield of 1.84% with the Annual cash Dividend per share of $1.2. The last quarter cash dividend per share pay out was $0.33. ResMed has a 5 year average dividend yield of 1.64% and the stock has a Indicated annual dividend of $1.32. ResMed (RMD) formally announced its most recent dividend on January 24, 2017 with a Dividend per share of $0.33. The new indicated annual dividend based on announced dividend per share is $1.32. The dividend yield based on the forward looking indicated annual dividend is 1.84%. ResMed (RMD) has the most recent dividend payout ratio of 0.48 with a 5-year average payout ratio of 0.37. The Ex-Dividend amount last paid was $0.33 on February 7, 2017. Companys change in pay out ratio when compared to the last 5 years average pay out ratio has been 0.11. The 5 year historical dividend growth of ResMed (RMD) is at the rate of 29.3% while the R-Squared dividend growth is 0.52. If the value of R-Square is close to one, it indicates a perfect fit and the higher value conforms to the regression line while data close to zero indicates the opposite.
ResMed Inc. (NYSE:RMD) rose 0.31% or 0.22 points on Thursday and made its way into the gainers of the day. After trading began at $72.07 the stock was seen hitting $72.3 as a peak level and $71.455 as the lowest level. The stock ended up at $71.92. The daily volume was measured at 584,946 shares. The 52-week high of the share price is $72.3 and the 52-week low is $55.13. The company has a market cap of $10,188 million. Shares of ResMed Inc. rose by 3.04% in the last five trading days and 14.18% for the last 4 weeks. ResMed Inc. is up 23.49% in the last 3-month period. Year-to-Date the stock performance stands at 16.47%.
Currently the company Insiders own 1.97% of ResMed Inc. shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -4.39% . Institutional Investors own 62.51% of ResMed Inc. shares. During last six month period, the net percent change held by insiders has seen a change of -16.45%. Company has reported several Insider transactions to the SEC, on Feb 7, 2017, Peter C Farrell (director) sold 20,000 shares at 68.32 per share price.On Feb 6, 2017, David Pendarvis (Chief Administrative Officer) sold 6,365 shares at 67.16 per share price.On Jan 19, 2017, James Hollingshead (President, Americas) sold 7,084 shares at 64.44 per share price.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.ResMed was Upgraded by JP Morgan to Overweight on Jan 24, 2017. Company shares were Reiterated by Canaccord Genuity on Jan 24, 2017 to Hold, Raises Price Target to $ 59 from a previous price target of $55 .
ResMed Last issued its quarterly earnings results on Jan 23, 2017. The company reported $0.73 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $0.70. The company had revenue of $530.40 million for the quarter, compared to analysts expectations of $516.28 million. The companys revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.69 EPS.
ResMed Inc. is a leading designer, manufacturer and distributor of medical equipment for treating and diagnosing sleep disordered breathing. Sleep disordered breathing includes sleep apnea and related respiratory conditions. The company sells a comprehensive range of diagnostic and treatment devices in countries through a combination of wholly owned subsidiaries and independent distributors.